{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:35:31Z","timestamp":1790876131522,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to maintain the patient in a delicate immunologic balance in which, while antitumor therapy defeats cancer the graft is safely protected from rejection. Recent clinical trials with ICPI have included kidney transplant recipients (KTRs) and the results advocate for a paradigm shift in the management of basal immunosuppression. This suggests that downward adjustments should be avoided or, even better, that this adjustment should be \u201cdynamic.\u201d This review summarizes the latest scientific evidence available in renal transplantation under ICPI treatment: case series, prospective studies, histopathologic diagnosis, immunosuppression regimens and new biomarkers. This article will provide the latest information in on this specific field, allowing nephrologists to gain valuable knowledge and to be aware of new approaches to immunosuppression management in oncological kidney transplant patients.<\/jats:p>","DOI":"10.3389\/ti.2024.13204","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T23:11:21Z","timestamp":1732489881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits"],"prefix":"10.3389","volume":"37","author":[{"given":"M\u00f3nica","family":"Bolufer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Taco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mac\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in Cancer Incidence and Outcomes Among Kidney Transplant Recipients in the United States Over a Thirty-Year Period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in Kidney Transplant Recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/01.tp.0000120181.89206.54","article-title":"Pro- and Anti-Cancer Effects of Immunosuppressive Agents Used in Organ Transplantation","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2215\/CJN.03500412","article-title":"Association Between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile in CKD in CRIC","volume":"7","author":"Gupta","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12882-018-0828-2","article-title":"Quantification of Cancer Risk in Glomerulonephritis","volume":"19","author":"Heaf","year":"2018","journal-title":"BMC Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/03008916241229649","article-title":"How Many Italian Cancer Patients Are Eligible for, and May Respond to, Italian Medicines Agency-Approved Immune Checkpoint Inhibitors?","volume":"110","author":"Crocetti","year":"2024","journal-title":"Tumori"},{"key":"B7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A Multi-Center Study on Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients with Kidney Transplant","volume":"100","author":"Murakami","year":"2020","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.3390\/antib8040051","article-title":"Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors","volume":"8","author":"Gravbrot","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3390\/v13101951","article-title":"Chronic LCMV Infection Is Fortified With Versatile Tactics to Suppress Host T Cell Immunity and Establish Viral Persistence","volume":"13","author":"Studstill","year":"2021","journal-title":"Viruses"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8056","DOI":"10.1128\/JVI.68.12.8056-8063.1994","article-title":"CD4+ T Cells Are Required to Sustain CD8+ Cytotoxic T-Cell Responses During Chronic Viral Infection","volume":"68","author":"Matloubian","year":"1994","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"109696","DOI":"10.1016\/j.celrep.2021.109696","article-title":"CD4 T Cell Help Prevents CD8 T Cell Exhaustion and Promotes Control of Mycobacterium tuberculosis Infection","volume":"36","author":"Lu","year":"2021","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1002\/ctm2.629","article-title":"Deep Phenotyping of T Cell Populations Under Long-Term Treatment of Tacrolimus and Rapamycin in Patients Receiving Renal Transplantations by Mass Cytometry","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.4049\/jimmunol.2000736","article-title":"Functional Characteristics and Phenotypic Plasticity of CD57+PD1- CD4 T Cells and Their Relationship With Transplant Immunosuppression","volume":"206","author":"Shaw","year":"2021","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"sfae061","DOI":"10.1093\/ckj\/sfae061","article-title":"Fine-Tuning Tumor- and Allo-Immunity: Advances in the Use of Immune Checkpoint Inhibitors in Kidney Transplant Recipients","volume":"17","author":"Van Meerhaeghe","year":"2024","journal-title":"Clin Kidney J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-Derived Cell-free DNA Detects Kidney Transplant Rejection During Nivolumab Treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2022.40.16_suppl.9507","article-title":"Nivolumab (NIVO) + Tacrolimus (TACRO) + Prednisone (PRED) +\/- Ipilimumab (IPI) for Kidney Transplant Recipients (KTR) With Advanced Cutaneous Cancers","volume":"40","author":"Schenk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S1470","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A Multicentre, Single-Arm, Phase 1 Study","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e170191","DOI":"10.1172\/JCI170191","article-title":"Single-cell Transcriptomic Analysis of Renal Allograft Rejection Reveals Insights into Intragraft TCR Clonality","volume":"133","author":"Shi","year":"2023","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics Prediction of Immune-Related Adverse Events during Checkpoint Immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4285\/kjt.22.0013","article-title":"Immune Checkpoint Inhibitors for Solid Organ Transplant Recipients: Clinical Updates - PubMed","volume":"36","author":"Kawashima","year":"2022","journal-title":"Korean J Transpl"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor Outcomes with the Use of Checkpoint Inhibitors in Kidney Transplant Recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients: A Patient-Centered Systematic Review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2021.01.038","article-title":"Transplant Rejections Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review","volume":"148","author":"Nguyen","year":"2021","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune Checkpoint Inhibitor Nephrotoxicity: What Do We Know and What Should We Do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103169","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the Knowledge Gap of Immune Checkpoint Inhibitors in Chronic Renal Failure: A Systematic Review of the Literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients With Metastatic Cutaneous Squamous Cell Carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"The Oncologist"},{"key":"B27","volume-title":"A Phase 1\/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers","year":"2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + Tacrolimus + Prednisone \u00b1 Ipilimumab for Kidney Transplant Recipients with Advanced Cutaneous Cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2020.01.012","article-title":"Solid Organ Transplant Rejection Associated with Immune-Checkpoint Inhibitors","volume":"31","author":"Saberianfar","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.nefroe.2023.11.001","article-title":"Adverse Renal Effects of Check-Point Inhibitors (ICI) in Cancer Patients: Recommendations of the Onco-Nephrology Working Group of the Spanish Society of Nephrology","volume":"43","author":"Alonso","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint Inhibitor Therapy for Cancer in Solid Organ Transplantation Recipients: An Institutional Experience and a Systematic Review of the Literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2217\/imt-2021-0195","article-title":"Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review","volume":"14","author":"Rossi","year":"2022","journal-title":"Immunotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2215\/CJN.00920121","article-title":"Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events","volume":"16","author":"Adam","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2022.08.010","article-title":"Immune Checkpoint Blockade for Organ-Transplant Recipients With Cancer: A Review","volume":"175","author":"R\u00fcnger","year":"2022","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients","volume":"5","author":"Manohar","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and Tolerance of Immune Checkpoint Inhibitors in Transplant Patients with Cancer: A Systematic Review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transpl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of Corticosteroids on Allograft Protection in Renal Transplant Patients Receiving Anti-PD-1 Immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01498","article-title":"Safety and Efficacy of Cemiplimab (PD-1 Blockade) in Selected Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC)","author":"Hanna","year":"2024","journal-title":"clinicaltrials.gov"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4369574","DOI":"10.1155\/2016\/4369574","article-title":"Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J Transpl"},{"key":"B43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semnephrol.2022.01.003","article-title":"Emerging Concepts in Managing Malignancy in Kidney Transplant Patients","volume":"42","author":"Schreiber","year":"2022","journal-title":"Semin Nephrol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.kint.2020.07.012","article-title":"KDIGO Controversies Conference on Onco-Nephrology: Kidney Disease in Hematological Malignancies and the Burden of Cancer after Kidney Transplantation","volume":"98","author":"Ma\u0142yszko","year":"2020","journal-title":"Kidney Int"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T23:11:24Z","timestamp":1732489884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":45,"alternative-id":["10.3389\/ti.2024.13204"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.13204","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"article-number":"13204"}}